Anna Wiksten

486 total citations
11 papers, 340 citations indexed

About

Anna Wiksten is a scholar working on Rheumatology, Statistics, Probability and Uncertainty and Pathology and Forensic Medicine. According to data from OpenAlex, Anna Wiksten has authored 11 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Rheumatology, 3 papers in Statistics, Probability and Uncertainty and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Anna Wiksten's work include Meta-analysis and systematic reviews (3 papers), Spondyloarthritis Studies and Treatments (3 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Anna Wiksten is often cited by papers focused on Meta-analysis and systematic reviews (3 papers), Spondyloarthritis Studies and Treatments (3 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Anna Wiksten collaborates with scholars based in Switzerland, Finland and Germany. Anna Wiksten's co-authors include Juhani Ruutiainen, Gerta Rücker, Eija Rosti‐Otajärvi, Päivi Hämäläinen, Guido Schwarzer, Atul Deodhar, Stephen Hall, Denis Poddubnyy, Sibylle Haemmerle and Ricardo Blanco and has published in prestigious journals such as Pain, Annals of the Rheumatic Diseases and Statistics in Medicine.

In The Last Decade

Anna Wiksten

11 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Wiksten Switzerland 9 132 103 66 64 39 11 340
Thomas Langenegger Switzerland 11 312 2.4× 34 0.3× 50 0.8× 99 1.5× 16 0.4× 17 413
Frane Grubišić Croatia 11 155 1.2× 72 0.7× 47 0.7× 30 0.5× 33 0.8× 52 324
T. Uhlig Norway 11 536 4.1× 151 1.5× 63 1.0× 218 3.4× 78 2.0× 18 707
Raphael I. Kieval United States 7 134 1.0× 23 0.2× 18 0.3× 9 0.1× 16 0.4× 7 303
Carole Desthieux France 6 272 2.1× 84 0.8× 55 0.8× 103 1.6× 30 0.8× 9 372
A. Ghali France 10 76 0.6× 38 0.4× 26 0.4× 77 1.2× 69 1.8× 26 308
Maria Reynolds United States 9 75 0.6× 10 0.1× 16 0.2× 25 0.4× 48 1.2× 19 346
Carolina Pérez-García Spain 13 166 1.3× 81 0.8× 16 0.2× 72 1.1× 16 0.4× 38 371
Khaldoon Alawneh Jordan 12 97 0.7× 48 0.5× 52 0.8× 60 0.9× 9 0.2× 29 305
J. Kekow Germany 8 223 1.7× 45 0.4× 60 0.9× 118 1.8× 27 0.7× 13 332

Countries citing papers authored by Anna Wiksten

Since Specialization
Citations

This map shows the geographic impact of Anna Wiksten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Wiksten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Wiksten more than expected).

Fields of papers citing papers by Anna Wiksten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Wiksten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Wiksten. The network helps show where Anna Wiksten may publish in the future.

Co-authorship network of co-authors of Anna Wiksten

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Wiksten. A scholar is included among the top collaborators of Anna Wiksten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Wiksten. Anna Wiksten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Braun, Jürgen, Ricardo Blanco, Helena Marzo‐Ortega, et al.. (2021). Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Research & Therapy. 23(1). 231–231. 21 indexed citations
2.
Wiksten, Anna, Neil Hawkins, Hans‐Peter Piepho, & Sandro Gsteiger. (2020). Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value in Health. 23(7). 918–927. 25 indexed citations
3.
Braun, Jürgen, Ricardo Blanco, Eva Dokoupilová, et al.. (2020). OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY. Annals of the Rheumatic Diseases. 79. 69–70. 5 indexed citations
4.
Deodhar, Atul, Ricardo Blanco, Eva Dokoupilová, et al.. (2020). Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study. Arthritis & Rheumatology. 73(1). 110–120. 113 indexed citations
5.
Steckelings, U. Muscha, Björn Dahlöf, Thomas Unger, et al.. (2018). Demonstration of Preclinical Efficacy in Pulmonary Fibrosis Models and of Clinical Safety, Tolerability, and Pharmacodynamic Effects of the First-in-Class Angiotensin AT2-Receptor Agonist Compound 21 (C21). University of Southern Denmark Research Portal (University of Southern Denmark). 1 indexed citations
6.
Moore, Andrew, Sheena Derry, Philip J Wiffen, et al.. (2018). Estimating relative efficacy in acute postoperative pain: network meta-analysis is consistent with indirect comparison to placebo alone. Pain. 159(11). 2234–2244. 10 indexed citations
7.
Steckelings, U. Muscha, Petri J. Vainío, Björn Dahlöf, et al.. (2017). [PP.02.17] SUCCESSFUL COMPLETION OF A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE TRIAL FOR THE FIRST IN CLASS ANGIOTENSIN AT2-RECEPTOR AGONIST COMPOUND 21. Journal of Hypertension. 35(Supplement 2). e105–e106. 11 indexed citations
8.
Rosti‐Otajärvi, Eija, et al.. (2017). Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients. Brain and Behavior. 7(7). e00743–e00743. 70 indexed citations
9.
Rosti‐Otajärvi, Eija, et al.. (2017). Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale‐29. Brain and Behavior. 7(7). e00725–e00725. 18 indexed citations
10.
Wiksten, Anna, Gerta Rücker, & Guido Schwarzer. (2016). Hartung–Knapp method is not always conservative compared with fixed‐effect meta‐analysis. Statistics in Medicine. 35(15). 2503–2515. 53 indexed citations
11.
Ahtiala, Maarit, et al.. (2014). Occurrence of Pressure Ulcers and Risk Factors in a Mixed Medical-Surgical ICU — A Cohort Study. Journal of the Intensive Care Society. 15(4). 340–343. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Langenegger Breakdown of academic impact, for papers by Frane Grubišić Breakdown of academic impact, for papers by T. Uhlig Breakdown of academic impact, for papers by Raphael I. Kieval Breakdown of academic impact, for papers by Carole Desthieux Breakdown of academic impact, for papers by A. Ghali Breakdown of academic impact, for papers by Maria Reynolds Breakdown of academic impact, for papers by Carolina Pérez-García Breakdown of academic impact, for papers by Khaldoon Alawneh Breakdown of academic impact, for papers by J. Kekow
Rankless by CCL
2026